KYNB

Kyntra Bio, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$3.59

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %103.1 / %30

Non-compliant assets / Total market cap %65.4 / %30

Non-compliant revenue / Total income %92.6 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Website

Analysis (Turkish): KYNB Hissesi Caiz mi, Helal mi? Kyntra Bio, Inc. Katılım Analizi